Houston's San Jacinto College is launching a biotechnology program in early 2024 to be housed in the Center for Biotechnology in Generation Park. Rendering courtesy of McCord

Houston's San Jacinto College will roll out a new biotechnology program in early 2024 as it gets closer to its goal of launching the Center for Biotechnology in Generation Park.

In partnership with the Ireland-based National Institute for Bioprocessing Research and Training, the licensed training curriculum will offer regional biopharmaceutical training at the college's South Campus starting in January.

Initially, the 90-hour hybrid training program will provide opportunities for participants to gain experience with "all aspects of biomanufacturing, specialized instrumentation and equipment training, and advanced techniques," according to a statement. Students will earn an onboarding certificate that will help them enter the field.

The college then plans to open the Center for Biotechnology, developed by McCord Development Inc., at its Generation Park Campus in the first quarter of 2025. The state-of-the-art facility is slated to allow for more hands-on training within simulated environments, and will allow students to earn associate of applied science degrees in biomanufacturing technology, as well as credentials for those already in the workforce.

“The biomanufacturing industry is seeing substantial growth in the Greater-Houston area,” Christopher Wild, executive director for the San Jacinto College Center for Biotechnology, says in a statement. “The College’s partnership to offer NIBRT’s premier, industry-leading training right here in the Houston-area represents a firm commitment to bolstering the biomanufacturing workforce pipeline which will help position the region for continued growth.”

The center will also offer programs that are customizable to industry partners' needs, according to a statement, and will provide cost-effective training for new hires. It will be the only NIBRT-licensed training in the Southwest and Southeast region.

“The NIBRT team have been very impressed by San Jacinto’s excellent track record in developing workforce programmes for the Greater Houston Region across a broad range of industrial sectors," Darrin Morrissey, CEO of NIBRT, says in a statement. We are very much looking forward to working with the San Jacinto team to deliver world class biopharma training programs to their students."

The new center is part of Generation Park, a 4,300-acre master-planned development in Northeast Houston. In late 2022, San Jac and McCord, which is developing Generation Park, shared that they had signed a memorandum of understanding with the NIBRT to launch the program and center.

At the time, San Jacinto College was slated to be the institute’s sixth global partner and second U.S. partner.

Over the summer, McCord also revealed plans for its 45-acre biomanufacturing campus at Generation Park.
Generation Park has announced additional biomanufacturing facility development. Rendering courtesy of McCord

Real estate company unveils plans for 45-acre biomanufacturing campus in Northeast Houston

life science upgrade

A Houston-based real estate company has reveals its plans to create a 45-acre biomanufacturing campus in the first phase of a life science development in Generation Park.

McCord Development released its plans for BioHub Two this week. The project will include 500,000 square feet for manufacturing, lab, and office space located in Generation Park, a 4,300-acre master-planned development in Northeast Houston.

The news of the BioHub follows Generation Park's December announcement of the San Jacinto College’s Biotech Training Center, a project in partnership with the National Institute of Biotechnology Research and Training. The institute will have a "bioprocessing pilot plant operated in a realistic GMP simulated and operational manufacturing environment," according to a news release from McCord.

“Houston has consistently been ranked as a burgeoning life science cluster, and BioHub Two has the unique advantage of being a short walk from the region’s only Biotech Training Center at San Jacinto College’s Generation Park campus," says John Flournoy, senior director of sales and leasing.

Last year, the Greater Houston Partnership released data showing the potential for the Bayou City as a hub for biomanufacturing, cell and gene therapy, cancer treatment, drug development, and more. Earlier this summer, Houston maintained its standing as a hub for life sciences on an annual report from CBRE.

“Houston’s high concentration of life sciences employment, healthy funding landscape, access to the Texas’ $6 billion CPRIT grant fund, and commitment to translational research is making it one of the country’s fastest growing life science ecosystems,” says Ryan McCord, president of McCord Development, in the release. “BioHub Two’s location in Generation Park is strategic and cost-effective, as the world-leading research and development facilities at the Texas Medical Center, Houston International Airport and Port of Houston are in close proximity.”

The larger Generation Part plans include two multifamily complexes, a mixed-use development called The Commons, and retail and green spaces.

The Texas Medical Center unveiled its plans for the TMC BioPort, a biomanufacturing and medical supplies distribution engine, almost a year ago. This new campus will span several hundred acres just down the road from TMC and will drive the much-needed repatriation of critical medical supplies and new cell and gene therapies, per a news release.

The opening of the pilot plant marks the debut of Cemvita’s eCO2 business as a wholly owned subsidiary. Photo courtesy of Cemvita

Fast-growing startup with carbon-free solution sets up pilot plant in Houston

big moves

Cleantech startup Cemvita has set up a pilot plant in its hometown of Houston to develop technology for converting carbon emissions as feedstock to make products like fertilizer, plastics, methane, and fuel.

The opening of the pilot plant marks the debut of Cemvita’s eCO2 business as a wholly owned subsidiary. The term eCO2 refers to equivalent carbon dioxide, or a way to measure a combination of greenhouse gases such as carbon dioxide and methane.

With a capacity of more than 14,000 gallons, the plant is producing eCO2 oil, an alternative to soybean oil. The company already is shipping samples of eCO2 products to customers, including renewable-fuel companies and plastics manufacturers.

Cemvita says the biofuel industry is facing feedstock shortages and price fluctuations. Biofuel feedstocks produce starches or sugars that can be converted to produce ethanol, while others produce oil that can be used in biodiesel production, according to the Sustainable Agriculture Research & Education (SARE) program.

“Traditional biofuels, including renewable diesel and sustainable aviation fuel, have relied on oils derived from crops, such as soybean and corn, as well as recycled vegetable oils,” Cemvita says. “As demand grows for petroleum-free alternatives, feedstock is in short supply and must compete with food markets. Crops of soybeans, sugar, and corn use huge swaths of land, and the raw materials require extensive refining — two factors that impede the processes from being sustainable.”

By contrast, eCO2 plants like Cemvita’s can supply feedstock production with minimal land and electricity requirements, and without relying on hydrogen or sunlight, the company says. Furthermore, the output of eCO2 plants is designed to carbon-negative, not just carbon-neutral.

Cemvita’s eCO2 biomanufacturing platform uses engineered microbes that absorb and convert carbon dioxide into feedstocks and finished products.

“The energy transition requires completely new, cost-effective approaches for heavy industry,” Charlie Nelson, chief operating officer of Cemvita, says in a news release. “We built this next-generation pilot plant in response to strong demand from … partners who are actively seeking sustainable solutions to the … feedstock shortage.”

Brother-and-sister team Moji and Tara Karimi founded Cemvita in 2017.

Investors in Cemvita include Oxy Low Carbon Ventures, an investment arm of Houston-based Occidental Petroleum, as well as BHP Group, Mitsubishi, and United Airlines Ventures.

Oxy Low Carbon Ventures and United Airlines Ventures are financing Cemvita’s work on sustainable jet fuel. United Airlines operates a hub at George Bush Intercontinental Airport Houston.

Veronica Wu, founder of First Bight Ventures, joins the Houston Innovators Podcast to outline Houston's opportunities in synthetic biology and biomanufacturing. Photo courtesy

Investor advocates now is the time to position Houston as a leading biomanufacturing hub

houston innovators podcast episode 178

Houston has all the ingredients to be a successful synthetic biology hub, says Veronica Wu. She believes so strongly in this that she relocated to Houston from Silicon Valley just over a year ago to start a venture capital firm dedicated to the field. Since then, she's doubled down on her passion for Houston leading in biotech — especially when it comes to one uniquely Houston opportunity: biomanufacturing.

While Houston's health care innovation scene is actively deploying synthetic biology applications, Wu points to Houston-based Solugen, a plant-based chemical producer, as an example of what Houston has to offer at-scale industrial biomanufacturing. Houston has the workforce and the physical space available for more of these types of biomanufacturing plants, which have a huge potential to move the needle on reducing carbon emissions.

"This is really fundamental technology that's going to change the paradigm and whole dialogue of how we are making a significant impact in reducing a carbon footprint and improving sustainability," says Wu, founder and managing partner of First Bight Ventures, on the Houston Innovators Podcast.

Several aspects — government funding, corporate interest, advances in technology — have converged to make it an ideal time for synthetic biology innovators and investors, Wu explains on the show, and she has an idea of what Houston needs to secure its spot as a leader in the space: The BioWell.

First introduced at a Houston Tech Rodeo event at the Texas Medical Center's Innovation Factory, The BioWell is a public-private partnership that aims to provide access to pilot and lab space, mentorship and programming, and more support that biomanufacturing innovators critically need.

"The way we envision The BioWell is it will provide a holistic, curated support for startups to be able to get across the Valley of Death," Wu says, explaining that startups transitioning from research and development into commercialization need extra support. The BioWell will provide that, as well as allow more engagement from corporations, investors, and other players.

Now that her plans for The BioWell have been announced, Wu is looking for those who want to be a part of it.

She shares more about her mission and what's next for First Bight Ventures on the podcast. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

San Diego-based rBIO moved to Houston to take advantage of the growing ecosystem of biomanufacturing and synthetic biology. Photo via Getty Images

California-founded biotech startup relocates to join Houston's emerging bioeconomy

new to hou

Cameron Owen had an idea for a synthetic biology application, and he pitched it to a handful of postdoctoral programs. When he received the feedback that he didn't have enough research experience, he decided to launch a startup based in San Diego around his idea. He figured that he'd either get the experience he needed to re-apply, or he'd create a viable company.

After three years of research and development, Owen's path seems to have taken him down the latter of those two options, and he moved his viable company, rBIO, to Houston — a twist he didn't see coming.

“Houston was not on my radar until about a year and a half ago,” Owen says, explaining that he thought of Houston as a leading health care hub, but the coasts still had an edge when it came to what he was doing. “San Diego and the Boston area are the two big biotech and life science hubs.”

But when he visited the Bayou City in December of 2021, he says he saw first hand that something new was happening.

“Companies from California like us and the coastal areas were converging here in Houston and creating this new type of bioeconomy,” he tells InnovationMap.

Owen moved to Houston last year, but rBIO still has an academic partner in Washington University in St. Louis and a clinical research organization it's working with too, so he admits rBIO's local footprint is relatively small — but not for long.

"When we look to want to get into manufacturing, we definitely want to build something here in Houston," he says. "We’re just not to that point as a company."

In terms of the stage rBIO is in now, Owen says the company is coming out of R&D and into clinical studies. He says rBIO has plans to fundraise and is meeting with potential partners that will help his company scale and build out a facility.

With the help of its CRO partner, rBIO has two ongoing clinical projects — with a third coming next month. Owen says right now rBIO is targeting the pharmaceutical industry’s biologics sector — these are drugs our bodies make naturally, like insulin. About 12 percent of the population in the United States has diabetes, which translates to almost 40 million people. The demand for insulin is high, and rBIO has a way to create it — and at 30 percent less cost.

This is just the tip of the iceberg — the world of synthetic biology application is endless.

“Now that we can design and manipulate biology in ways we’ve never been able to before,” Owen says, "we’re really only limited by our own imagination.”

Synthetic biology is a field of science that involves programing biology to create and redesign natural elements. While it sounds like science fiction, Owen compares it to any other type of technology.

“Biology really is a type of software,” he says. “Phones and computers at their core run on 1s and 0s. In biology, it’s kind of the same thing, but instead of two letters, it’s four — A, C, T, and G.”

“The cool thing about biology is the software builds the hardware,” he continues. “You put that code in there and the biology builds in and of itself.”

Owen says the industry of synthetic biology has been rising in popularity for years, but the technology has only recently caught up.

“We’re exploring a brave new world — there’s no doubt about that,” Owen says.

The new development will allow PackGene to nearly triple its Houston-area workforce by the end of the year when the facility is expected to be completed. Photo courtesy of PackGene

Gene therapy company breaks ground on Houston biomanufacturing facility

new to hou

China-based and Massachusetts-founded PackGene Biotech Inc. broke ground last week on a new 25,000-square-foot biomanufacturing and processing facility just south of NRG Park.

The full-service operations center is slated to include labs, manufacturing clean rooms, warehouse, and office space. According to a release from the company, PackGene already employs about 20 people at an existing space in Houston. The new development will allow the company to nearly triple its Houston-area workforce by the end of the year when the facility is expected to be completed.

E&K Building Group is providing design-build services on the project, and the architect of record is Perkins + Will.

"These capabilities will enable us to serve our U.S. customers better and, importantly, to help bring life-saving therapies to patients faster, more reliably, and more cost- effectively. With this, we are making great strides in advancing our mission of 'making gene therapy affordable'," LiYing Yang, PackGene's CTO, says in a statement.

PackGene, which also has facilities in Shanghai and Boston, is a leader in adeno-associated virus (AAV) research, development and manufacturing. It works to accelerate gene therapy product development and works with customers to support gene therapy programs from early-stage therapeutic discovery to clinical trials.

Late last year, a report showed that Houston was expected to see growth in life sciences development, including in the gene therapy manufacturing field. The Texas Medical Center also revealed its plans for the Bioport.

In light of the report, the GHP recommended a few action items, including "accelerating workforce development programs to produce new graduates in key life sciences occupations, refining Houston’s marketing messages to highlight the region’s existing life science assets and activities within life science R&D and manufacturing," per the report. Additionally, the GHP identified the need to develop a shared regional strategy to attract and retain leading life sciences companies.

About a month later, San Jacinto College in Houston announced that it would launch a new College Biotechnology Center at Generation Park in Northeast Houston. The college said the program would offer a specific curriculum in cell and gene therapy as well as hands-on experience in a pilot-scale bioprocessing center.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Trailblazing Houston entrepreneur brings big ideas to new Yahoo Finance show

tune in

Elizabeth Gore, co-founder and president of Houston's Hello Alice, debuted the first episode of her new video podcast series with Yahoo Finance on Thursday, April 24.

The weekly series, known as "The Big Idea with Elizabeth Gore," will focus on providing information and resources to small business owners and sharing stories of entrepreneurship, according to a news release from Yahoo Finance.

“Entrepreneurs and small business owners drive our country’s economy forward. With a record number of small businesses launching in our communities, my goal is to help every citizen live the American Dream. On the Big Idea, we will break down barriers for entrepreneurs and lift up opportunities for every person wanting to be their own boss,” Gore said in the release.

“By hosting the 'Big Idea' on Yahoo Finance, I’m looking forward to elevating business owners’ stories and providing actionable insights to small business owners at a scale like never before. I am blown away to be joining the number one finance news source that is already trusted by so many.”

Gore was joined by Hello Alice co-founder and CEO Carolyn Rodz in the premiere episode, titled "Got a big idea for a small business? Here's your first step," to discuss the steps they took when launching the business.

Gore and Rodz founded Hello Alice in 2017. The fintech platform supports over 1.5 million small businesses across the nation. It has helped owners access affordable capital and credit and distributed over $57 million in grants to businesses across various industries. The company raised a series C round backed by Mastercard last year for an undisclosed amount and reported that the funding brought the company's valuation up to $130 million at the time.

According to Yahoo Finance, Gore's experience and expertise build on its "mission to be the trusted guide of financial information to all investors, and democratize access to quality content."

“Over the past year, we invested in expanding our programming lineup with the launch of new shows and podcasts, and welcomed new financial creators and influencers into our newsroom,” Anthony Galloway, head of content at Yahoo Finance, added the release. “By diversifying our programming and talent roster, Yahoo Finance is introducing unique points-of-view that make financial topics more engaging, actionable, and personalized. Small business owners are a vital part of our audience, so we’re excited to welcome Elizabeth Gore from Hello Alice, whose insights and expertise will help us serve and connect with this important cohort in meaningful ways.”

The show is available on Spotify, Apple Podcasts, iHeart, Pandora, and Amazon Music for listening. Streamers can view it on yahoofinance.com, Amazon Prime Video, Samsung TV, Fire TV, Vizio, Haystack, DirectTV and other streaming platforms. Watch the premiere here:

7 top Houston researchers join Rice innovation cohort for 2025

top of class

The Liu Idea Lab for Innovation and Entrepreneurship (Lilie) has announced its 2025 Rice Innovation Fellows cohort, which includes students developing cutting-edge thermal management solutions for artificial intelligence, biomaterial cell therapy for treating lymphedema, and other innovative projects.

The program aims to support Rice Ph.D. students and postdocs in turning their research into real-world solutions and startups.

“Our fourth cohort of fellows spans multiple industries addressing the most pressing challenges of humanity,” Kyle Judah, Lilie’s executive director, said in a news release. “We see seven Innovation Fellows and their professors with the passion and a path to change the world.”

The seven 2025 Innovation Fellows are:

Chen-Yang Lin, Materials Science and Nanoengineering, Ph.D. 2025

Professor Jun Lou’s Laboratory

Lin is a co-founder of HEXAspec, a startup that focuses on creating thermal management solutions for artificial intelligence chips and high-performance semiconductor devices. The startup won the prestigious H. Albert Napier Rice Launch Challenge (NRLC) competition last year and also won this year's Energy Venture Day and Pitch Competition during CERAWeek in the TEX-E student track.

Sarah Jimenez, Bioengineering, Ph.D. 2027

Professor Camila Hochman-Mendez Laboratory

Jimenez is working to make transplantable hearts out of decellularized animal heart scaffolds in the lab and the creating an automated cell delivery system to “re-cellularize” hearts with patient-derived stem cells.

Alexander Lathem, Applied Physics and Chemistry, Ph.D. 2026

Professor James M. Tour Laboratory

Lathem’s research is focused on bringing laser-induced graphene technology from “academia into industry,” according to the university.

Dilrasbonu Vohidova is a Bioengineering, Ph.D. 2027

Professor Omid Veiseh Laboratory

Vohidova’s research focuses on engineering therapeutic cells to secrete immunomodulators, aiming to prevent the onset of autoimmunity in Type 1 diabetes.

Alexandria Carter, Bioengineering, Ph.D. 2027

Professor Michael King Laboratory

Carter is developing a device that offers personalized patient disease diagnostics by using 3D culturing and superhydrophobicity.

Alvaro Moreno Lozano, Bioengineering, Ph.D. 2027

Professor Omid Veiseh Lab

Lozano is using novel biomaterials and cell engineering to develop new technologies for patients with Type 1 Diabetes. The work aims to fabricate a bioartificial pancreas that can control blood glucose levels.

Lucas Eddy, Applied Physics and Chemistry, Ph.D. 2025

Professor James M. Tour Laboratory

Eddy specializes in building and using electrothermal reaction systems for nanomaterial synthesis, waste material upcycling and per- and polyfluoroalkyl substances (PFAS) destruction.

This year, the Liu Lab also introduced its first cohort of five commercialization fellows. See the full list here.

The Rice Innovation Fellows program assists doctoral students and postdoctoral researchers with training and support to turn their ideas into ventures. Alumni have raised over $20 million in funding and grants, according to Lilie. Last year's group included 10 doctoral and postdoctoral students working in fields such as computer science, mechanical engineering and materials science.

“The Innovation Fellows program helps scientist-led startups accelerate growth by leveraging campus resources — from One Small Step grants to the Summer Venture Studio accelerator — before launching into hubs like Greentown Labs, Helix Park and Rice’s new Nexus at The Ion,” Yael Hochberg, head of the Rice Entrepreneurship Initiative and the Ralph S. O’Connor Professor in Entrepreneurship, said in the release. “These ventures are shaping Houston’s next generation of pillar companies, keeping our city, state and country at the forefront of innovation in mission critical industries.”

Houston startup Collide secures $5M to grow energy-focused AI platform

Fresh Funds

Houston-based Collide, a provider of generative artificial intelligence for the energy sector, has raised $5 million in seed funding led by Houston’s Mercury Fund.

Other investors in the seed round include Bryan Sheffield, founder of Austin-based Parsley Energy, which was acquired by Dallas-based Pioneer Natural Resources in 2021; Billy Quinn, founder and managing partner of Dallas-based private equity firm Pearl Energy Investments; and David Albin, co-founder and former managing partner of Dallas-based private equity firm NGP Capital Partners.

“(Collide) co-founders Collin McLelland and Chuck Yates bring a unique understanding of the oil and gas industry,” Blair Garrou, managing partner at Mercury, said in a news release. “Their backgrounds, combined with Collide’s proprietary knowledge base, create a significant and strategic moat for the platform.”

Collide, founded in 2022, says the funding will enable the company to accelerate the development of its GenAI platform. GenAI creates digital content such as images, videos, text, and music.

Originally launched by Houston media organization Digital Wildcatters as “a professional network and digital community for technical discussions and knowledge sharing,” the company says it will now shift its focus to rolling out its enterprise-level, AI-enabled solution.

Collide explains that its platform gathers and synthesizes data from trusted sources to deliver industry insights for oil and gas professionals. Unlike platforms such as OpenAI, Perplexity, and Microsoft Copilot, Collide’s platform “uniquely accesses a comprehensive, industry-specific knowledge base, including technical papers, internal processes, and a curated Q&A database tailored to energy professionals,” the company said.

Collide says its approximately 6,000 platform users span 122 countries.

---

This story originally appeared on our sister site, EnergyCapitalHTX.com.